{"id":172,"date":"2019-01-29T15:49:09","date_gmt":"2019-01-29T06:49:09","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=172"},"modified":"2022-01-14T15:44:09","modified_gmt":"2022-01-14T06:44:09","slug":"publications2013","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/publications2013\/","title":{"rendered":"2013"},"content":{"rendered":"

\u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09<\/strong><\/h4>\n
    \n
  1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u3068\u65b0\u898f\u6cbb\u7642\u3078\u306e\u5fdc\u7528,\u300c\u304c\u3093\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u3000\u5225\u518a\u300d,11(2), 55-58, 2013<\/li>\n
  2. \u79cb\u5c71\u5ee3\u8f14,\u3000\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3068\u6cbb\u7642\u611f\u53d7\u6027,\u300c\u6700\u65b0\u533b\u5b66\u300d,68(12), 40-45, 2013<\/li>\n
  3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f50\u85e4\u9756\u53f2\uff0c\u9ad9\u5009\u4f38\u5e78\u7de8\uff0c\u8840\u7ba1\u65b0\u751f\u7814\u7a76\u306e\u6700\u5148\u7aef\uff0c\u201c\u8840\u7ba1\u65b0\u751f\u3068\u75c5\u614b\uff0d\u816b\u760d\u8840\u7ba1\u65b0\u751f\u201d\uff0c254-262\uff0c\u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb\u793e\uff0c2013\uff08\u5206\u62c5\u57f7\u7b46\uff09<\/li>\n<\/ol>\n

    \u82f1\u6587\u7dcf\u8aac<\/h4>\n
      \n
    1. *Hida K<\/u>., Ohga N., Akiyama K., Maishi N., Hida Y.\uff1aHeterogeneity of tumor endothelial cells,\u00a0Cancer Sci<\/em><\/strong>, 104(11), 1391-1395, 2013<\/li>\n
    2. *Hida K<\/u>.<\/u>, Akiyama K., Ohga N., Maishi N., Hida Y.: Tumor endothelial cells acquire drug resistance in a tumor microenvironment,\u00a0J Biochem,<\/em><\/strong>\u00a0153(3), 243-249, 2013<\/li>\n<\/ol>\n

      \u82f1\u8a9e\u8ad6\u6587<\/strong><\/h4>\n
        \n
      1. Kondoh M.\u00a7<\/strong>, Ohga N.\u00a7<\/strong>, Akiyama K.\u00a7<\/strong>, Hida Y., Maishi N., Towfik AM., Inoue N., Shindoh M. and *Hida K.<\/u>\uff1aHypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment,\u00a0PLoS ONE<\/em><\/strong>, 8(11), e80349, 2013<\/li>\n
      2. Akhter A., Hayashi Y., Sakurai Y., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aA liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence\uff0cInt J Pharm<\/em><\/strong>\uff0c456(1)\uff0c195-201, 2013<\/li>\n
      3. Osawa T., Ohga N., Akiyama K., Hida Y., Kitayama K., Kawamoto T., Yamamoto K. , Maishi N., Kondoh M., Onodera Y., Fujie M., Nonomura K., Shindoh M. and\u00a0*Hida K<\/u>. : Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis,\u00a0Br J Cancer<\/em><\/strong>, 109(8), 2237-2247, 2013<\/li>\n
      4. Maishi N., Kawamoto T., Ohga N.,Yamad K., Akiyama K., Yamamoto K. , Osawa T., Hida Y. and\u00a0*Hida K<\/u>.<\/u>\u00a0:\u00a0<\/strong>Application of POLARIC\u2122 fluorophores in an\u00a0in vivo\u00a0<\/em>tumor model,\u00a0Oncol Rep<\/em><\/strong>, 30(4), 1695-1700, 2013<\/li>\n
      5. Kibria G., Hatakeyama H., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aThe effect of liposomal size on the targeted delivery of doxorubicin to Integrin alpha v beta 3-expressing tumor endothelial cells,\u00a0Biomaterials<\/em><\/strong>, 34(22), 5617-5627, 2013<\/li>\n
      6. Nagamine K., Kitamura T., Yanagawa -Matsuda A., Ohiro Y., Tei K.,\u00a0Hida K.<\/u>, Higashino F., Totsuka Y. and Shindoh M.\uff1a Expression of parathyroid hormone-related protein confers malignant potential to mucoepidermoid carcinoma,\u00a0Oncol Rep<\/em><\/strong>, 29(6), 2114-2118, 2013<\/li>\n
      7. Yamada Y., Hashida M., Hayashi Y., Tabata M., Hyodo M., Ara MN., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aAn approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid,\u00a0J Pharm Sci,<\/em><\/strong>102(9), 3119-3127, 2013<\/li>\n
      8. Akiyama K., Ohga N., Maishi N., Hida Y., Kitayama K., Kawamoto T., Osawa T., Suzuki Y., Shinohara N., Nonomura K., Shindoh M, *Hida K<\/u>\u00a0: The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma,\u00a0Pathol Int,<\/em><\/strong>63(1), 37-44, 2013\u00a0\u3014PDF\u3015<\/a><\/li>\n<\/ol>\n

        \u62db\u5f85\u8b1b\u6f14<\/strong><\/h4>\n
          \n
        1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c36\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u300c\u30de\u30a4\u30af\u30edRNA\u3068\u30a8\u30af\u30bd\u30bd\u30fc\u30e0\u306e\u751f\u7269\u5b66\u7684\u610f\u7fa9\u300d,\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3068miRNA\u201d,2013.12.5\uff08\u795e\u6238\uff09<\/li>\n
        2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c3\u56de\u5317\u6d77\u9053\u63a2\u7d22\u75c5\u7406\u5b66\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u63a2\u7d22\u533b\u7642\u30fb\u57fa\u790e\u3068\u81e8\u5e8a\u306e\u9023\u643a\uff1a\u75c5\u7406\u304c\u6a4b\u6e21\u3057\u3059\u308b\u81e8\u5e8a\u7814\u7a76\u306e\u65b0\u5c55\u958b\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u660e\u304b\u3089\u8a3a\u65ad\u30fb\u6cbb\u7642\u3078\u306e\u5fdc\u7528\u201d\uff0c2013.11.9\uff08\u672d\u5e4c\uff09<\/li>\n
        3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\u7279\u5225\u8b1b\u6f14,\u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u3068\u304c\u3093\u306e\u6d78\u6f64\u8ee2\u79fb\u201d,2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
        4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u304c\u3093\u3068\u5fae\u5c0f\u74b0\u5883\uff1a\u7814\u7a76\u306e\u5c55\u671b\u300d,\u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u201d,2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
        5. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u816b\u760d\u8840\u7ba1\u65b0\u751f\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u62b5\u6297\u6027\u201d, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
        6. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c25\u56de\u5317\u6d77\u9053\u8f38\u8840\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff0c\u201c\u816b\u760d\u8840\u7ba1\u65b0\u751f\u3068\u304c\u3093\u306e\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u201d\uff0c2013.7.26\uff08\u672d\u5e4c\uff09<\/li>\n
        7. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u3068\u8840\u7ba1\u65b0\u751f, \u7b2c22\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2013.7.12\uff08\u677e\u672c\uff09<\/li>\n
        8. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, \u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u201d, 2013.4.18\uff08\u4eac\u90fd\uff09<\/li>\n<\/ol>\n

          \u56fd\u5185\u5b66\u4f1a\u767a\u8868<\/h4>\n
            \n
          1. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b, \u5927\u5ee3\u6d0b\u4e00, \u5c0f\u91ce\u8ca2\u4f38,\u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50Vasohibin-1\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
          2. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT,\u3000\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u6a19\u7684\u3068\u3057\u305f\u30e1\u30c8\u30ed\u30ce\u30df\u30c3\u30af\u30b1\u30e2\u30bb\u30e9\u30d4\u30fc\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
          3. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272, \u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
          4. \u5927\u6751\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u9593\u77f3\u5948\u6e56\uff0cAlam MT\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
          5. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b,\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38,\u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50Vasohibin-1\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
          6. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1amicrovesicles\u3092\u4ecb\u3057\u3066\u816b\u760d\u7d30\u80de\u7531\u6765\u306emiRNA\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3078\u8f38\u9001\u3055\u308c\u308b\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
          7. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aP-gp\u963b\u5bb3\u5264\u306f\u30e1\u30c8\u30ed\u30ce\u30df\u30c3\u30af\u30b1\u30e2\u30bb\u30e9\u30d4\u30fc\u306e\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u52b9\u679c\u3092\u5f37\u3081\u308b\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
          8. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d,\u79cb\u5c71\u5ee3\u8f14,\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT, \u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
          9. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50,\u3000\u5927\u6751\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u30fb\u4f4e\u6804\u990a\u5faa\u74b0\u306b\u3088\u308bROS\u306e\u84c4\u7a4d\u304c\u53ca\u307c\u3059TEC\u3078\u306e\u5f71\u97ff\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
          10. \u5c71\u7530\u5065\u53f8,\u9593\u77f3\u5948\u6e56,\u5927\u8cc0\u5247\u5b5d,\u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT, \u9032\u85e4\u6b63\u4fe1\uff0c\u9ad8\u6a4b\u5178\u5f66,\u795e\u5c71\u4fca\u54c9, \u6a0b\u7530\u6cf0\u6d69\uff0c\u6b66\u51a8\u7d39\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7\u306e\u6628\u65e5\u89e3\u6790, \u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
          11. Alam MT, \u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4, \u91ce\u3005\u6751\u514b\u4e5f\uff0c\u571f\u5c4b\u90a6\u5f66, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aSBSN is a novel Tumor Endothelial Cell marker, \u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
          12. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived miRNA is transported to endothelial cells by microvesicles\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.27\uff08\u5927\u962a\uff09<\/li>\n
          13. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT, \u9ad8\u6a4b\u5178\u5f66\uff0c\u795e\u5c71\u4fca\u54c9, \u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7 \u306e\u6a5f\u80fd\u89e3\u6790, \u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
          14. \u5317\u689d\u656c\u4e4b, \u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50,\u89d2\u8c37\u3000\u77b3, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u30fb\u4f4e\u6804\u990a\u306b\u3088\u308a\u8a98\u5c0e\u3055\u308c\u308bROS\u304c\u53ca\u307c\u3059\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u306e\u5f71\u97ff\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
          15. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
          16. \u6c38\u5c3e\u5b97\u5b50, Alam MT\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4,\u6b66\u51a8\u7d39\u4fe1,\u6a0b\u7530\u6cf0\u6d69,\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aSBSN is a novel Tumor Endothelial Cell maker, \u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
          17. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3057\u305fMetronomic Chemotherapy\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
          18. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived miRNA is transported to endothelial cells by microvesicles\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
          19. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u89d2\u8c37\u77b3, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u85e4\u6fa4\u4fca\u660e,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u6804\u990a\u306b\u3088\u308a\u8a98\u5c0e\u3055\u308c\u308bROS\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u53ca\u307c\u3059\u5f71\u97ff\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
          20. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aP-gp \u963b\u5bb3\u5264\u306f\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b, \u7b2c22\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a,2013.7.12\uff08\u677e\u672c\uff09<\/li>\n
          21. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT\uff0c\u5927\u6751\u3000\u77b3\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\uff0c\u7b2c22\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a,2013.7.12\uff08\u677e\u672c\uff09<\/li>\n
          22. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u6751\u3000\u77b3\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u4e0e\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
          23. Alam MT, \u5927\u8cc0\u5247\u5b5d\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u306f\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u95a2\u9023\u56e0\u5b50\u3067\u3042\u308b, \u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
          24. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT, \u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
          25. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT,\u3000\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3057\u305fMetronomic Chemotherapy\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
          26. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam MT, \u5927\u6751\u3000\u77b3\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9ad8\u6a4b\u5178\u5f66\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7 \u306e\u6a5f\u80fd\u89e3\u6790,\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.6\uff08\u672d\u5e4c\uff09<\/li>\n
          27. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT,\u3000 \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u30d9\u30e9\u30d1\u30df\u30eb\u306f\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.24\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
          28. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.24\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
          29. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7d30\u80de\u7531\u6765\u306emicrovesicle\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eproangiogenic phenotype\u3092\u5f15\u304d\u8d77\u3053\u3059\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
          30. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d,\u3000\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6751\u3000\u77b3\uff0c\u4e95\u4e0a\u8fb2\u592b\u7537\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
          31. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam MT, \u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            \u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09 \u6a0b\u7530\u4eac\u5b50\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u3068\u65b0\u898f\u6cbb\u7642\u3078\u306e\u5fdc\u7528,\u300c\u304c\u3093\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u3000\u5225\u518a\u300d,11(2), 55-58, 2013 \u79cb\u5c71\u5ee3\u8f14,\u3000\u6a0b\u7530\u4eac\u5b50\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3068\u6cbb\u7642\u611f\u53d7\u6027,\u300c\u6700\u65b0\u533b\u5b66\u300d,68(12), 40-45, 2013 \u6a0b\u7530\u4eac\u5b50\uff1a\u4f50\u85e4\u9756\u53f2\uff0c\u9ad9\u5009\u4f38\u5e78\u7de8\uff0c\u8840\u7ba1\u65b0\u751f\u7814\u7a76\u306e\u6700\u5148\u7aef\uff0c\u201c\u8840\u7ba1\u65b0\u751f\u3068\u75c5\u614b\uff0d\u816b\u760d\u8840\u7ba1\u65b0\u751f\u201d\uff0c254-262\uff0c\u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb\u793e\uff0c2013\uff08\u5206\u62c5\u57f7\u7b46\uff09 \u82f1\u6587…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-172","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=172"}],"version-history":[{"count":3,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/172\/revisions"}],"predecessor-version":[{"id":877,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/172\/revisions\/877"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}